Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $56.57.

AGIO has been the topic of a number of analyst reports. Royal Bank of Canada lifted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 target price on the stock. Scotiabank lifted their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $32.71 on Friday. Agios Pharmaceuticals has a 1 year low of $27.14 and a 1 year high of $62.58. The firm has a fifty day moving average price of $33.44 and a 200-day moving average price of $41.43. The company has a market cap of $1.87 billion, a price-to-earnings ratio of 2.88 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities research analysts expect that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insiders Place Their Bets

In other news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock valued at $185,045,000 after buying an additional 85,339 shares in the last quarter. State Street Corp raised its position in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after buying an additional 216,484 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at about $97,199,000. Jefferies Financial Group Inc. purchased a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at about $49,290,000. Finally, Geode Capital Management LLC raised its position in shares of Agios Pharmaceuticals by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after buying an additional 6,101 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.